AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...

The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc ...

Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

Biden Allows Ukraine to Strike Russia With Long-Range U.S. Missiles President Biden for the first time authorized the use of a system known as ATACMS to help defend Ukraine’s forces in the Kursk ...

Why the iPhone SE 4 Could Be One of Apple's Most Important Products of 2025 ...

The Conservative leader said he will work to bring foreign investment and industry back to Canada with policies similar to Trump's vows to slash taxes and regulations.

Stewart-Haas' sad demise belies its legacy of unlikely success (October 31, 2024, 7:00 PM ET) ...